Bioject Medical Technologies, a leading developer and manufacturer of needle-free injection technology, has announced that it has entered into a distribution agreement with Fondaco PTE, LTD, a premier medical supplies company based in Singapore. Under the terms of this agreement, Fondaco will be the exclusive distributor of Bioject's commercial needle-free injection products in Singapore, Indonesia, and Malaysia.
Products positioned for distribution through this agreement include the full portfolio of Bioject technologies including the Biojector® 2000 needle-free injection system and theBioject® ZetaJet™ portable injector. In September 2013, Bioject also announced an international distribution agreement with iHealthnet LLC for distribution of Bioject products in markets including South Asia, India and the Middle East.
"We have seen significant demand for advanced needle-free technologies in global markets including Asia in recent years. Through collaboration with established industry leaders such as Fondaco, we will be ideally positioned to expand our product marketing focus in this region in the years ahead. Together we have the full range of expertise and insight to bring the significant advantages of needle-free drug delivery to millions more patients in the years ahead," said Mark Logomasini, President and CEO of Bioject.
The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and is expected to reach $43.3 billion by 2017. Recent reports indicate that the market for injectable technologies is positioned to grow rapidly in Asia
Bioject Medical Technologies, a leading developer and manufacturer of needle-free injection technology, has announced that it has entered into a distribution agreement with Fondaco PTE, LTD, a premier medical supplies company based in Singapore.